Compass Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 13.42 million compared to USD 11.59 million a year ago. Basic loss per share from continuing operations was USD 0.11 compared to USD 0.1 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.46 USD | +0.69% | -3.95% | -6.41% |
Apr. 25 | Compass Therapeutics Gets FDA Fast-Track Designation for Biliary Tract Cancer Treatment | MT |
Apr. 25 | Compass Therapeutics Gets FDA Fast-Track for Cancer Treatment | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.41% | 200M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- CMPX Stock
- News Compass Therapeutics, Inc.
- Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023